PUBLIC COMPANY
saveIPSEN
USupdated 14d ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
- —A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China
- phase3A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
- —A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
- —A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain
- —A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
- phase2A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
- —Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
🐶 Hiring Signal
News
- ‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryBioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.fiercebiotech · 8h ago
- Ipsen has 'firepower' for more deals with €2B war chestIpsen has its eyes trained on more M&A — and has €2 billion worth of “firepower” to do it, based on its cash position at the end of June, CFO Aymeric Le Chatelier said. “If we ...endpoints · 15d ago
- Ipsen’s Bylvay fails key trial in children with rare liver diseaseIpsen disclosed that Bylvay failed a Phase 3 study for biliary atresia, a serious liver disease that leads the bile ducts to become blocked in babies. Babies with the disease can get a Kasai proced…endpoints · 21d ago
- Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialPlus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…endpoints · 1mo ago
- ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.biopharma_dive · 1mo ago
- Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfrontPlus news on Alchemab, Scipher and Forte. 💉 Ipsen’s Dysport aces Phase 3 migraine trials: The biotech’s injectable neurotoxin met the primary endpoint of reducing monthly migraine days in two ...endpoints · 1mo ago
- Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first halfBiopharma's M&A engine is revved up and shows no signs of cooling off. Four companies have announced acquisitions in the first six days of July, forging deals that could pay out as much as $12.6 ...endpoints · 1mo ago
- Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M dealThe purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.biopharma_dive · 1mo ago
- STAT+: More signs that GLP-1s may help with peripheral artery diseaseAnthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readoutstat · 1mo ago
- Ipsen to scoop up Memo Therapeutics and its kidney infection drugIpsen is on an M&A roll. The French drugmaker announced its second deal of the week, saying it would buy Memo Therapeutics and its drug candidate called potravitug for a viral ...endpoints · 1mo ago
comments(0)
5-min edit window · permanent after that